Z. Velkovski, Maja Belevska, Emilija Gjosevska Dastevska
{"title":"ASSESSMENT OF THE SOCIAL BURDEN ON PATIENTS WITH PRIMARY OPEN-ANGLE GLAUCOMA","authors":"Z. Velkovski, Maja Belevska, Emilija Gjosevska Dastevska","doi":"10.5633/amm.2021.0405","DOIUrl":"https://doi.org/10.5633/amm.2021.0405","url":null,"abstract":"","PeriodicalId":31409,"journal":{"name":"Acta Medica Medianae","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49334014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Golubovic, Velimir Perić, M. Lazarević, T. Kostić, D. Stokanović, M. Djordjevic, V. Marjanovic, D. Milic
{"title":"RCRI VS. GSCRI IN SIX-MONTHS PREDICTION OF MYOCARDIAL INFARCTION AND CARDIAC ARREST OCCURRENCE","authors":"M. Golubovic, Velimir Perić, M. Lazarević, T. Kostić, D. Stokanović, M. Djordjevic, V. Marjanovic, D. Milic","doi":"10.5633/amm.2021.0401","DOIUrl":"https://doi.org/10.5633/amm.2021.0401","url":null,"abstract":"","PeriodicalId":31409,"journal":{"name":"Acta Medica Medianae","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46501841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
V. Cvetanović, I. Veselinović, V. Dinic, A. Nikolić, M. Stojanovic, Milica Marković, Marko Gmijović
{"title":"ULTRASOUND-GUIDED CENTRAL VEIN CANNULATION","authors":"V. Cvetanović, I. Veselinović, V. Dinic, A. Nikolić, M. Stojanovic, Milica Marković, Marko Gmijović","doi":"10.5633/amm.2021.0311","DOIUrl":"https://doi.org/10.5633/amm.2021.0311","url":null,"abstract":"","PeriodicalId":31409,"journal":{"name":"Acta Medica Medianae","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48776844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Kostić, Aleksandra Stojanovic, M. Stankovic, O. Zikic
{"title":"STRUCTURED ASSESSMENT OF VIOLENCE RISK IN YOUTH IN CLINICAL PRACTICE","authors":"J. Kostić, Aleksandra Stojanovic, M. Stankovic, O. Zikic","doi":"10.5633/amm.2021.0308","DOIUrl":"https://doi.org/10.5633/amm.2021.0308","url":null,"abstract":"","PeriodicalId":31409,"journal":{"name":"Acta Medica Medianae","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48922254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Catić Djordjević, N. Stefanović, Ana Spasić, I. Damnjanovic, R. Veličković Radovanović, B. Djindjic, Dusko Pavlovic
{"title":"CURRENT OVERVIEW OF COVID-19 VACCINATION PROCESS IN SERBIA","authors":"A. Catić Djordjević, N. Stefanović, Ana Spasić, I. Damnjanovic, R. Veličković Radovanović, B. Djindjic, Dusko Pavlovic","doi":"10.5633/amm.2021.0303","DOIUrl":"https://doi.org/10.5633/amm.2021.0303","url":null,"abstract":"","PeriodicalId":31409,"journal":{"name":"Acta Medica Medianae","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41694857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Vujović, E. Kostić, Dimitrije Pančić, B. Milosavljevic, I. Stojanović, Radovan Karadžič, G. Ilić
{"title":"PREGABALIN DETERMINATION IN POSTMORTEM SAMPLES AND TOXICOLOGICAL SIGNIFICANCE IN FORENSIC CASES","authors":"M. Vujović, E. Kostić, Dimitrije Pančić, B. Milosavljevic, I. Stojanović, Radovan Karadžič, G. Ilić","doi":"10.5633/amm.2021.0301","DOIUrl":"https://doi.org/10.5633/amm.2021.0301","url":null,"abstract":"","PeriodicalId":31409,"journal":{"name":"Acta Medica Medianae","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48467444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
B. Djordjevic, T. Cvetković, T. Jevtović Stoimenov, M. Despotović, A. Veljković, J. Bašić, A. Veličkov, Jelena Milenković, A. Marjanović, Milica Randjelović, Vladana Stojiljkovic, D. Sokolović
{"title":"THE RELATIONSHIP BETWEEN SERUM CONCENTRATION OF TNF- AND INSULIN SENSITIVITY IN RATS WITH DIABETES MELLITUS TYPE 2","authors":"B. Djordjevic, T. Cvetković, T. Jevtović Stoimenov, M. Despotović, A. Veljković, J. Bašić, A. Veličkov, Jelena Milenković, A. Marjanović, Milica Randjelović, Vladana Stojiljkovic, D. Sokolović","doi":"10.5633/amm.2021.0306","DOIUrl":"https://doi.org/10.5633/amm.2021.0306","url":null,"abstract":"","PeriodicalId":31409,"journal":{"name":"Acta Medica Medianae","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43653583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
D. Lazarević, Marija Ratković Janković, M. Jakovljević, J. Vojinović
In the last decade, tumor necrosis factor- (TNF-) inhibitors have shown excellent control of ocular inflammation in juvenile idiopathic arthritis (JIA)-associated uveitis. We have retrospectively evaluated the long-term efficacy and safety of adalimumab in 19 biologically naive patients with JIA-associated uveitis from our biologic registry. Demographic data and blood samples were collected at different time points. Uveitis activity was evaluated by slit-lamp biomicroscopy. Adverse events were recorded. The registry records provided a ten-year follow-up of 11 (57.90%) female patients diagnosed with oligo/extended oligoarticular JIA-associated uveitis and 8 (42.10%) males diagnosed with enthesitis-related arthritis (ERA) with uveitis. Adalimumab was the first biologic prescribed to JIA patients with active uveitis that failed to respond to standard treatment. A tenyear long follow-up period has shown that there were no new relapsis of uveitis while patients were receiving adalimumab and metotrexate. All of our patients after adalimumab introduction were able to gradually tapper and stop treatment with topical steroids. Thirty-six point eighty-four percent of our patients were able to stop biological treatment 36 months after adalimumab commencing. Uveitis has relapsed three monts after the adalimumab discontinuation only in two patients (10.53%). No serious adverse events were recorded. Thirty-one point fifty-eight percent of patients expirienced minor adverse events. During a long-term follow-up, adalimumab showed good efficacy and safety profile in JIA patients with active inflammatory ocular disease. Acta Medica Medianae 2021;60(3):30-36.
{"title":"LONG TERM EFFICACY AND SAFETY OF ADALIMUMAB IN JUVENILE IDIOPATHIC ARTHRITIS (JIA) ASSOCIATED UVEITIS","authors":"D. Lazarević, Marija Ratković Janković, M. Jakovljević, J. Vojinović","doi":"10.5633/amm.2021.0304","DOIUrl":"https://doi.org/10.5633/amm.2021.0304","url":null,"abstract":"In the last decade, tumor necrosis factor- (TNF-) inhibitors have shown excellent control of ocular inflammation in juvenile idiopathic arthritis (JIA)-associated uveitis. We have retrospectively evaluated the long-term efficacy and safety of adalimumab in 19 biologically naive patients with JIA-associated uveitis from our biologic registry. Demographic data and blood samples were collected at different time points. Uveitis activity was evaluated by slit-lamp biomicroscopy. Adverse events were recorded. The registry records provided a ten-year follow-up of 11 (57.90%) female patients diagnosed with oligo/extended oligoarticular JIA-associated uveitis and 8 (42.10%) males diagnosed with enthesitis-related arthritis (ERA) with uveitis. Adalimumab was the first biologic prescribed to JIA patients with active uveitis that failed to respond to standard treatment. A tenyear long follow-up period has shown that there were no new relapsis of uveitis while patients were receiving adalimumab and metotrexate. All of our patients after adalimumab introduction were able to gradually tapper and stop treatment with topical steroids. Thirty-six point eighty-four percent of our patients were able to stop biological treatment 36 months after adalimumab commencing. Uveitis has relapsed three monts after the adalimumab discontinuation only in two patients (10.53%). No serious adverse events were recorded. Thirty-one point fifty-eight percent of patients expirienced minor adverse events. During a long-term follow-up, adalimumab showed good efficacy and safety profile in JIA patients with active inflammatory ocular disease. Acta Medica Medianae 2021;60(3):30-36.","PeriodicalId":31409,"journal":{"name":"Acta Medica Medianae","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41927112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：